Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts.
Nicolini
A
A
Second Medical Clinic, University of Pisa, Italy.
Carpi
A
A
Ferrari
P
P
Anselmi
L
L
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000401:mortality / Q000601:surgery; D002272:Carcinoembryonic Antigen / Q000097:blood; D005069:Evaluation Studies as Topic; D005260:Female; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D018396:Mucin-1 / Q000097:blood; D009363:Neoplasm Proteins / Q000097:blood*; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis; D011184:Postoperative Period; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D019396:Tissue Polypeptide Antigen / Q000097:blood
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C072700:CA549 glycoprotein, human; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins; D018396:Mucin-1; D009363:Neoplasm Proteins; D019396:Tissue Polypeptide Antigen; C057387:mucinous carcinoma-associated antigen